

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

Brilliant Violet 421(TM) anti-human CD45RA

RRID:AB_10900421

Type: Antibody

Proper Citation

BioLegend Cat# 304129, RRID:AB_10900421

Antibody Information

URL: http://antibodyregistry.org/AB_10900421

Proper Citation: BioLegend Cat# 304129, RRID:AB_10900421

Target Antigen: CD45RA

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-P

Antibody Name: Brilliant Violet 421(TM) anti-human CD45RA

Description: This monoclonal targets CD45RA

Target Organism: human

Clone ID: Clone HI100

Antibody ID: AB_10900421

Vendor: BioLegend

Catalog Number: 304129

Alternative Catalog Numbers: 304130

Record Creation Time: 20231110T063558+0000

Record Last Update: 20260828T231932+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD45RA.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD45RA.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Murdock BJ, et al. (2025) Early immune system changes in amyotrophic lateral sclerosis correlate with later disease progression. *Med (New York, N.Y.)*, 6(8), 100673.

Lin S, et al. (2025) Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. *iScience*, 28(5), 112497.

Martínez-Balboa Y, et al. (2025) Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. *iScience*, 28(8), 113167.

Tieu V, et al. (2024) A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. *Cell*, 187(5), 1278.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. *Clinical and experimental immunology*.

Giovenzana A, et al. (2024) Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesity. *iScience*, 27(3), 109032.

Jarosch S, et al. (2022) ChipCytometry for multiplexed detection of protein and mRNA markers on human FFPE tissue samples. *STAR protocols*, 3(2), 101374.

Erlandsson MC, et al. (2022) Survivin promotes a glycolytic switch in CD4+ T cells by suppressing the transcription of PFKFB3 in rheumatoid arthritis. *iScience*, 25(12), 105526.

Xu S, et al. (2021) Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. *Immunity*, 54(7), 1561.

Jarosch S, et al. (2021) Multiplexed imaging and automated signal quantification in formalin-fixed paraffin-embedded tissues by ChipCytometry. *Cell reports methods*, 1(7), 100104.

Sekine T, et al. (2020) Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*, 183(1), 158.

Sagnella SM, et al. (2020) Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. *Cancer cell*, 37(3), 354.